-
公开(公告)号：EP2734552B1
公开(公告)日：2024-11-13
申请号：EP12735916.4
申请日：2012-07-20
-
公开(公告)号：EP4458825A1
公开(公告)日：2024-11-06
申请号：EP22914529.7
申请日：2022-12-23
发明人： XI, Ning , LI, Xiaobo , LI, Minxiong , FENG, Xuejin
IPC分类号： C07D413/14 , A61K31/517 , A61P11/00 , A61P31/12 , A61P9/10 , A61P35/02 , A61P37/00
摘要： Provided are a salt of an aminopyrimidine compound and a use thereof. Specifically, provided are a salt of ( S )-2-(1-((6-amino-5-(3-methyl-1,2,4-oxadiazol-5-yl)pyrimidin-4-yl)amino)ethyl)-5-(3-hydroxypro p-1-yn-1-yl)-3-phenylquinazolin-4(3 H )-one and a pharmaceutical composition comprising the salt. Further provided is a use thereof in the preparation of a medicament for treating and preventing diseases related to PI3K kinase abnormalities.
-
公开(公告)号：EP4458362A1
公开(公告)日：2024-11-06
申请号：EP21969813.1
申请日：2021-12-31
发明人： QI, Youmao
IPC分类号： A61K31/724 , C12N9/72 , A61K31/365 , A61K9/08 , A61K9/16 , A61K9/19 , A61K9/28 , A61K9/48 , A61K9/00 , A61P7/02 , A61P9/10 , A61P43/00
摘要： Provided in the present invention are a cardiovascular and cerebrovascular drug and the use thereof. Specifically, the compound of the present invention has a structure as represented by formula (I), wherein each group is defined as described in the description. Further disclosed in the present invention is the use of the compound in treating thrombotic diseases, resisting inflammation and treating nerve injury.
-
公开(公告)号：EP4406595A3
公开(公告)日：2024-10-30
申请号：EP24182318.6
申请日：2018-03-06
发明人： SHERMAN, Craig
IPC分类号： A61K31/198 , A61K31/27 , A61K31/65 , A61K33/00 , A61P3/06 , A61P3/10 , A61P9/00 , A61M1/16 , A61P9/10 , A61P13/12
摘要： Provided herein are methods for maintaining physiological levels of nitrite in a subject undergoing hemodialysis and for preventing myocardial infarction, sudden cardiac death, stroke, high blood pressure, pulmonary hypertension, renal hypertension, or cardiovascular disease that is characterized by tissue ischemia including angina, cerebral vasospasm, claudication, critical limb ischemia, peripheral vascular disease and sickle cell crisis, in a subject undergoing hemodialysis. Also provided herein are methods of administering pharmaceutically acceptable sodium nitrite to a subject undergoing hemodialysis.
-
公开(公告)号：EP4450624A1
公开(公告)日：2024-10-23
申请号：EP22906685.7
申请日：2022-12-16
发明人： LI, Yunfei , DENG, Yongyan , HOU, Zhe , ZHANG, Jianyu , WANG, Yanhui , MAO, Song , HUANG, Jinyu , LIU, Nan , CAI, Guoqing , LV, Zhenzhen , HUANG, Yanfen , ZHOU, Yaqin , LUO, Min , ZHANG, Fang
IPC分类号： C12N15/113 , A61K47/54 , A61K48/00 , A61P9/10
摘要： The present invention relates to LPA-targeting siRNA and a conjugate, and specifically relates to LPA-targeting siRNA, a siRNA conjugate, a composition, and a pharmaceutical use thereof. The present invention also relates to a pharmaceutical composition, a cell or a kit comprising the siRNA, and a method for the siRNA and the siRNA conjugate for treating and/or preventing related disorders suffered by a subject.
-
公开(公告)号：EP4403214A3
公开(公告)日：2024-10-16
申请号：EP24175952.1
申请日：2018-12-21
申请人： Novartis AG
摘要： Provided herein are methods of treating, preventing, and managing metabolic or cardiovascular disorders and methods of reducing cardiovascular risk with FGF21 protein variants, including Fc-FGF21 variant fusion proteins.
-
7.发明授权
-
-
公开(公告)号：EP4434520A1
公开(公告)日：2024-09-25
申请号：EP22895692.6
申请日：2022-11-18
申请人： Shionogi & Co., Ltd.
发明人： YOSHIDA, Yasunobu , UNO USUI, Mai , SHIMAZAKI, Atsuyuki , YUKIOKA, Hideo , KASHIWAGI, Yuto , YAMADA, Tomomi
IPC分类号： A61K31/4184 , A61P3/06 , A61P3/10 , A61P7/00 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P13/12 , A61P21/00 , A61P43/00
CPC分类号： A61P9/04 , A61P43/00 , A61P7/00 , A61P9/00 , A61P3/10 , A61P9/10 , A61P13/12 , A61P21/00 , A61P3/06 , A61K31/4184 , A61P9/06
摘要： Provided is a pharmaceutical composition for treating and/or preventing at least one of heart diseases, heart disease complications, skeletal muscle diseases, and skeletal muscle conditions, the pharmaceutical composition having an excellent ACC2-selective inhibitory effect and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration.
A pharmaceutical composition for treating and/or preventing at least one of heart diseases, heart disease complications, skeletal muscle diseases, and skeletal muscle conditions, the pharmaceutical composition comprising a compound represented by Formula (I):
wherein R1 is haloalkyl or non-aromatic carbocyclyl,
R2 is a hydrogen atom or halogen,
R3 is halogen,
ring A is a group represented by the formula:
-L1- is -O-(CH2)-, -(CH2)2-, or the like,
R4 is alkyl or haloalkyl, and
R5 is alkylcarbonyl or carbamoyl,
or a pharmaceutically acceptable salt thereof.-
公开(公告)号：EP4385566A3
公开(公告)日：2024-09-18
申请号：EP24160044.4
申请日：2021-03-31
发明人： BHATTACHERJEE, Robin Chandra , COATS, Andrew Justin Stewart , MORTEN, Elaine , LAWRENCE, Ronnie Maxwell , RAEBURN, Jaclyn , LOBATO, Kiara Marissa , LOUGHREY, Jonathan James
IPC分类号： C07D209/32 , A61K31/405 , A61P9/10 , A61P9/12 , A61P21/00 , A61P25/22 , A61P27/06
CPC分类号： C07D209/32 , A61P21/00 , A61P9/12 , A61P9/10 , A61P27/06 , A61P25/22 , A61K31/404 , A61K9/20
摘要： The invention relates to a pharmaceutically acceptable acid addition salt of: (i) S-pindolol; and (ii) an organic acid, wherein the organic acid has: a pKa1 of greater than or equal to 2.5; and a chemical formula of CxHy(CO2H)z, where x is from 1 to 10, y is from 2 to 20 and z is 1 or 2. The pharmaceutically acceptable acid addition salt is useful in treating conditions such as cachexia, sarcopenia, a neuromuscular disorder and muscle weakness.
-
-
-
-
-
-
-
-
-
搜索结果
10977 条记录 (耗时 0.031 秒)
